Document Detail

Pseudoporphyria as a result of voriconazole use: a case report.
MedLine Citation:
PMID:  15485539     Owner:  NLM     Status:  MEDLINE    
Voriconazole, a second-generation triazole, has recently been approved by the Food and Drug Administration (FDA) to treat invasive aspergillosis and refractory infections with Scedosporium apiospermum or Fusarium spp. The reported side-effects of voriconazole include visual changes, headaches, elevated hepatic enzymes, Steven-Johnson syndrome, toxic epidermal necrolysis, chelitis, photosensitivity, discoid lupus erythematosus and anaphylactoid infusion reactions. Pseudoporphyria was first described in association with nalidixic acid. It has the same clinical and histologic features as porphyria cutanea tarda (PCT) but is distinguished by normal porphyrin levels in the serum, urine and stool. We present the case of a patient who developed pseudoporphyria after receiving treatment with voriconazole.
Christopher K Dolan; Mark A Hall; David L Blazes; Christopher W Norwood
Related Documents :
16757369 - Pancreatic sarcoidosis: unusual presentation resembling a periampullary malignancy.
2152059 - Systemic lupus erythematosus and miliary tuberculosis in a prepubertal girl--a case rep...
23669809 - Psoriasis and psoriatic arthropathy, historical aspects: part i.
6606399 - Sarcoid dactylitis.
23816569 - Reactive arthritis induced by intravesical bcg therapy for bladder cancer: our clinical...
7452639 - Acute lupus pneumonitis in the puerperium. a case report and literature review.
10788839 - Primary biliary cirrhosis and myopathy: an uncommon association.
22431869 - Systematic review of randomized controlled trials comparing intracapsular tonsillectomy...
21375769 - Carney complex: case report and review.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  International journal of dermatology     Volume:  43     ISSN:  0011-9059     ISO Abbreviation:  Int. J. Dermatol.     Publication Date:  2004 Oct 
Date Detail:
Created Date:  2004-10-15     Completed Date:  2005-01-24     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  0243704     Medline TA:  Int J Dermatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  768-71     Citation Subset:  IM    
United States Naval Reserve, Patuxent River Naval Medical Clinic, Patuxent River, MD, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antifungal Agents / administration & dosage,  adverse effects*
Diagnosis, Differential
Drug Eruptions / diagnosis*,  etiology,  pathology
Lung Diseases, Fungal / drug therapy*
Mycetoma / drug therapy*
Porphyria, Acute Intermittent / diagnosis*,  etiology,  pathology
Pyrimidines / administration & dosage,  adverse effects*
Triazoles / administration & dosage,  adverse effects*
Reg. No./Substance:
0/Antifungal Agents; 0/Pyrimidines; 0/Triazoles; 0/voriconazole
Comment In:
Int J Dermatol. 2006 Dec;45(12):1455   [PMID:  17184262 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Acne treated successfully with azithromycin.
Next Document:  Neuroprotective effects of melatonin against anoxia/aglycemia stress, as assessed by synaptic potent...